Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
13,544
archived clinical trials in
Ovarian Cancer

Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have Not Progressed After First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/31/1969
Novartis Investigational Site
mi
from
Orange, CA
Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have Not Progressed After First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/31/1969
Novartis Investigational Site
mi
from
Orange, CA
Click here to add this to my saved trials
Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have Not Progressed After First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
San Francisco, CA
Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have Not Progressed After First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
San Francisco, CA
Click here to add this to my saved trials
Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have Not Progressed After First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
San Jose, CA
Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have Not Progressed After First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
San Jose, CA
Click here to add this to my saved trials
Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have Not Progressed After First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Santa Clara, CA
Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have Not Progressed After First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Santa Clara, CA
Click here to add this to my saved trials
Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have Not Progressed After First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Vallejo, CA
Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have Not Progressed After First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Vallejo, CA
Click here to add this to my saved trials
Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have Not Progressed After First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Augusta, GA
Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have Not Progressed After First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Augusta, GA
Click here to add this to my saved trials
Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have Not Progressed After First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Morristown, NJ
Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have Not Progressed After First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Morristown, NJ
Click here to add this to my saved trials
Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have Not Progressed After First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/31/1969
Novartis
mi
from
New York, NY
Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have Not Progressed After First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/31/1969
Novartis
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have Not Progressed After First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Annandale, VA
Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have Not Progressed After First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Annandale, VA
Click here to add this to my saved trials
Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have Not Progressed After First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Camperdown,
Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have Not Progressed After First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Camperdown,
Click here to add this to my saved trials
Combination Chemotherapy, Bone Marrow Transplantation, and Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer
A PHASE I TRIAL OF HIGH DOSE CHEMOTHERAPY WITH AUTOLOGOUS BONE MARROW AND PERIPHERAL BLOOD PROGENITOR CELL RESCUE IN PATIENTS WITH PLATINUM-SENSITIVE, CHEMOTHERAPY-RESPONSIVE EPITHELIAL OVARIAN CARCINOMA
Status: Enrolling
Updated:  12/31/1969
Marlene & Stewart Greenebaum Cancer Center, University of Maryland
mi
from
Baltimore, MD
Combination Chemotherapy, Bone Marrow Transplantation, and Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer
A PHASE I TRIAL OF HIGH DOSE CHEMOTHERAPY WITH AUTOLOGOUS BONE MARROW AND PERIPHERAL BLOOD PROGENITOR CELL RESCUE IN PATIENTS WITH PLATINUM-SENSITIVE, CHEMOTHERAPY-RESPONSIVE EPITHELIAL OVARIAN CARCINOMA
Status: Enrolling
Updated: 12/31/1969
Marlene & Stewart Greenebaum Cancer Center, University of Maryland
mi
from
Baltimore, MD
Click here to add this to my saved trials
Combination Chemotherapy, Bone Marrow Transplantation, and Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer
A PHASE I TRIAL OF HIGH DOSE CHEMOTHERAPY WITH AUTOLOGOUS BONE MARROW AND PERIPHERAL BLOOD PROGENITOR CELL RESCUE IN PATIENTS WITH PLATINUM-SENSITIVE, CHEMOTHERAPY-RESPONSIVE EPITHELIAL OVARIAN CARCINOMA
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins Oncology Center
mi
from
Baltimore, MD
Combination Chemotherapy, Bone Marrow Transplantation, and Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer
A PHASE I TRIAL OF HIGH DOSE CHEMOTHERAPY WITH AUTOLOGOUS BONE MARROW AND PERIPHERAL BLOOD PROGENITOR CELL RESCUE IN PATIENTS WITH PLATINUM-SENSITIVE, CHEMOTHERAPY-RESPONSIVE EPITHELIAL OVARIAN CARCINOMA
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins Oncology Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Vaccine Therapy in Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
Phase I Study of ALVAC(2)-NY-ESO-1(M)/TRICOM (VCP2292) in Patients With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma Whose Tumors Express NY-ESO-1 or LAGE-1 Antigen
Status: Enrolling
Updated:  12/31/1969
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Vaccine Therapy in Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
Phase I Study of ALVAC(2)-NY-ESO-1(M)/TRICOM (VCP2292) in Patients With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma Whose Tumors Express NY-ESO-1 or LAGE-1 Antigen
Status: Enrolling
Updated: 12/31/1969
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Vaccine Therapy in Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
Phase I Study of ALVAC(2)-NY-ESO-1(M)/TRICOM (VCP2292) in Patients With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma Whose Tumors Express NY-ESO-1 or LAGE-1 Antigen
Status: Enrolling
Updated:  12/31/1969
NYU Cancer Institute at New York University Medical Center
mi
from
New York, NY
Vaccine Therapy in Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
Phase I Study of ALVAC(2)-NY-ESO-1(M)/TRICOM (VCP2292) in Patients With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma Whose Tumors Express NY-ESO-1 or LAGE-1 Antigen
Status: Enrolling
Updated: 12/31/1969
NYU Cancer Institute at New York University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial
A Randomized Phase II/III Trial of Intravenous (IV) Paclitaxel Weekly Plus IV Carboplatin Once Every 3 Weeks Versus IV Paclitaxel Weekly Plus Intraperitoneal (IP) Carboplatin Once Every 3 Weeks in Women With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh
mi
from
Pittsburgh, PA
Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial
A Randomized Phase II/III Trial of Intravenous (IV) Paclitaxel Weekly Plus IV Carboplatin Once Every 3 Weeks Versus IV Paclitaxel Weekly Plus Intraperitoneal (IP) Carboplatin Once Every 3 Weeks in Women With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial
A Randomized Phase II/III Trial of Intravenous (IV) Paclitaxel Weekly Plus IV Carboplatin Once Every 3 Weeks Versus IV Paclitaxel Weekly Plus Intraperitoneal (IP) Carboplatin Once Every 3 Weeks in Women With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/31/1969
Queen Mary Hospital
mi
from
Pok Fu Lam,
Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial
A Randomized Phase II/III Trial of Intravenous (IV) Paclitaxel Weekly Plus IV Carboplatin Once Every 3 Weeks Versus IV Paclitaxel Weekly Plus Intraperitoneal (IP) Carboplatin Once Every 3 Weeks in Women With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/31/1969
Queen Mary Hospital
mi
from
Pok Fu Lam,
Click here to add this to my saved trials
VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Phase I/II and Pharmacokinetic Study of Docetaxel Plus VEGF Trap (AVE0005, NSC# 724770) in Patients With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
Status: Enrolling
Updated:  12/31/1969
M D Anderson Cancer Center
mi
from
Houston, TX
VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Phase I/II and Pharmacokinetic Study of Docetaxel Plus VEGF Trap (AVE0005, NSC# 724770) in Patients With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
Status: Enrolling
Updated: 12/31/1969
M D Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Phase I/II and Pharmacokinetic Study of Docetaxel Plus VEGF Trap (AVE0005, NSC# 724770) in Patients With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
Status: Enrolling
Updated:  12/31/1969
University of Virginia Health System
mi
from
Charlottesville, VA
VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Phase I/II and Pharmacokinetic Study of Docetaxel Plus VEGF Trap (AVE0005, NSC# 724770) in Patients With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
Status: Enrolling
Updated: 12/31/1969
University of Virginia Health System
mi
from
Charlottesville, VA
Click here to add this to my saved trials
HER-2/Neu Vaccine Plus GM-CSF in Treating Patients With Stage III or Stage IV Breast, Ovarian, or Non-small Cell Lung Cancer
A Phase I Study of a HER-2/Neu Peptide Based Vaccine With GM-CSF as an Adjuvant in Patients With Advanced Stage HER-2/Neu Expressing Cancers
Status: Enrolling
Updated:  12/31/1969
University of Washington School of Medicine
mi
from
Seattle, WA
HER-2/Neu Vaccine Plus GM-CSF in Treating Patients With Stage III or Stage IV Breast, Ovarian, or Non-small Cell Lung Cancer
A Phase I Study of a HER-2/Neu Peptide Based Vaccine With GM-CSF as an Adjuvant in Patients With Advanced Stage HER-2/Neu Expressing Cancers
Status: Enrolling
Updated: 12/31/1969
University of Washington School of Medicine
mi
from
Seattle, WA
Click here to add this to my saved trials
Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors
TREATMENT OF CHILDREN AND YOUNG ADULTS WITH RECURRENT/REFRACTORY SOLID TUMORS WITH HIGH DOSE ETOPOSIDE AND CARBOPLATIN PLUS ESCALATING DOSE CYCLOPHOSPHAMIDE, FOLLOWED BY HEMATOPOIETIC RESCUE USING AUTOLOGOUS CD34+ SELECTED BLOOD STEM CELLS: A PILOT STUDY
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins Oncology Center
mi
from
Baltimore, MD
Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors
TREATMENT OF CHILDREN AND YOUNG ADULTS WITH RECURRENT/REFRACTORY SOLID TUMORS WITH HIGH DOSE ETOPOSIDE AND CARBOPLATIN PLUS ESCALATING DOSE CYCLOPHOSPHAMIDE, FOLLOWED BY HEMATOPOIETIC RESCUE USING AUTOLOGOUS CD34+ SELECTED BLOOD STEM CELLS: A PILOT STUDY
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins Oncology Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Web-Based Coping and Communication Skills Intervention in Improving Psychological Adaptation in Patients With Gynecological Cancer
Web-Based Coping and Communication Skills Intervention for Women Who Are Newly Diagnosed With Gynecological Cancer: A Pilot Study
Status: Enrolling
Updated:  12/31/1969
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Web-Based Coping and Communication Skills Intervention in Improving Psychological Adaptation in Patients With Gynecological Cancer
Web-Based Coping and Communication Skills Intervention for Women Who Are Newly Diagnosed With Gynecological Cancer: A Pilot Study
Status: Enrolling
Updated: 12/31/1969
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Genetic Counseling in African American Women
Genetic Counseling for Breast Cancer Susceptibility in African American Women
Status: Enrolling
Updated:  3/21/2007
Univ of Pennsylvania
mi
from
Philadelphia, PA
Genetic Counseling in African American Women
Genetic Counseling for Breast Cancer Susceptibility in African American Women
Status: Enrolling
Updated: 3/21/2007
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/5/2007
Seton Medical Mangement Dba Oncology Center at Providence Hospital
mi
from
Mobile, AL
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/5/2007
Seton Medical Mangement Dba Oncology Center at Providence Hospital
mi
from
Mobile, AL
Click here to add this to my saved trials
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/5/2007
Rocky Mountain Gynecology & Oncology
mi
from
Englewood, CO
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/5/2007
Rocky Mountain Gynecology & Oncology
mi
from
Englewood, CO
Click here to add this to my saved trials
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/5/2007
Florida Gynecologic Oncology
mi
from
Fort Myers, FL
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/5/2007
Florida Gynecologic Oncology
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/5/2007
Jupiter Medical Center-Gynecology Oncology and Gynecology
mi
from
Jupiter, FL
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/5/2007
Jupiter Medical Center-Gynecology Oncology and Gynecology
mi
from
Jupiter, FL
Click here to add this to my saved trials
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/5/2007
Florida Hospital/Gyn/Onc Department
mi
from
Orlando, FL
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/5/2007
Florida Hospital/Gyn/Onc Department
mi
from
Orlando, FL
Click here to add this to my saved trials
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/5/2007
Augusta Oncology Associates
mi
from
Augusta, GA
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/5/2007
Augusta Oncology Associates
mi
from
Augusta, GA
Click here to add this to my saved trials
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/5/2007
Med College of Georgia
mi
from
Augusta, GA
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/5/2007
Med College of Georgia
mi
from
Augusta, GA
Click here to add this to my saved trials
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/5/2007
Kapiolani Medical Center for Women and Children
mi
from
Honolulu, HI
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/5/2007
Kapiolani Medical Center for Women and Children
mi
from
Honolulu, HI
Click here to add this to my saved trials
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/5/2007
University of Illinois/Department of Gynecology Oncology
mi
from
Chicago, IL
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/5/2007
University of Illinois/Department of Gynecology Oncology
mi
from
Chicago, IL
Click here to add this to my saved trials
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/5/2007
Evanston North Health Care
mi
from
Evanston, IL
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/5/2007
Evanston North Health Care
mi
from
Evanston, IL
Click here to add this to my saved trials
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/5/2007
Hematology-Onc. Assoc. of The Quad Cities
mi
from
Bettendorf, IA
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/5/2007
Hematology-Onc. Assoc. of The Quad Cities
mi
from
Bettendorf, IA
Click here to add this to my saved trials
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/5/2007
University of Iowa
mi
from
Iowa City, IA
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/5/2007
University of Iowa
mi
from
Iowa City, IA
Click here to add this to my saved trials
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/5/2007
Hematology & Oncology Specialists/Dept. of OB/GYN
mi
from
New Orleans, LA
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/5/2007
Hematology & Oncology Specialists/Dept. of OB/GYN
mi
from
New Orleans, LA
Click here to add this to my saved trials
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/5/2007
Franklin Square Hospital Center/MedStar Health-Section of Hematology/Oncology
mi
from
Baltimore, MD
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/5/2007
Franklin Square Hospital Center/MedStar Health-Section of Hematology/Oncology
mi
from
Baltimore, MD
Click here to add this to my saved trials
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/5/2007
Saint Luke's Hospital of Kansas City/The Cancer Institute
mi
from
Kansas City, MO
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/5/2007
Saint Luke's Hospital of Kansas City/The Cancer Institute
mi
from
Kansas City, MO
Click here to add this to my saved trials
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/5/2007
Cancer Center at Hackensack
mi
from
Hackensack, NJ
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/5/2007
Cancer Center at Hackensack
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/5/2007
Columbia University College of Physicians and Surg
mi
from
New York, NY
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/5/2007
Columbia University College of Physicians and Surg
mi
from
New York, NY
Click here to add this to my saved trials
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/5/2007
Hope: A Woman's Cancer Center
mi
from
Asheville, NC
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/5/2007
Hope: A Woman's Cancer Center
mi
from
Asheville, NC
Click here to add this to my saved trials
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/5/2007
University of North Carolina/ Division of Gyn Oncology
mi
from
Chapel Hill, NC
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/5/2007
University of North Carolina/ Division of Gyn Oncology
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/5/2007
Carolinas Medical Center/Gyn Oncology Department
mi
from
Charlotte, NC
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/5/2007
Carolinas Medical Center/Gyn Oncology Department
mi
from
Charlotte, NC
Click here to add this to my saved trials
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/5/2007
Duke University/Division of Gynecologic Oncology
mi
from
Durham, NC
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/5/2007
Duke University/Division of Gynecologic Oncology
mi
from
Durham, NC
Click here to add this to my saved trials
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/5/2007
Moses H. Cone Health System/ Regional Cancer Center
mi
from
Greensboro, NC
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/5/2007
Moses H. Cone Health System/ Regional Cancer Center
mi
from
Greensboro, NC
Click here to add this to my saved trials
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/5/2007
Forsyth Regional Cancer Center
mi
from
Winston-Salem, NC
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/5/2007
Forsyth Regional Cancer Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/5/2007
Gynecologic Oncology and Surgery
mi
from
Oklahoma City, OK
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/5/2007
Gynecologic Oncology and Surgery
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/5/2007
PA Hematology/Oncology Associates
mi
from
Philadelphia, PA
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/5/2007
PA Hematology/Oncology Associates
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/5/2007
Western Pennsylvania Hospital
mi
from
Pittsburgh, PA
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/5/2007
Western Pennsylvania Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/5/2007
MUSC-Div of Gyn/Oncology
mi
from
Charleston, SC
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/5/2007
MUSC-Div of Gyn/Oncology
mi
from
Charleston, SC
Click here to add this to my saved trials
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/5/2007
The West Cancer Clinic
mi
from
Memphis, TN
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Multicenter, Randomized, Phase III Comparative Study to Compare the Efficacy and Safety of Taxotere®/Carboplatin Combination Therapy Versus Sequential Therapy With Taxotere® Then Carboplatin as Second-Line Treatment of Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/5/2007
The West Cancer Clinic
mi
from
Memphis, TN
Click here to add this to my saved trials